Discovery of the First Approved Covalent FGFR Inhibitor, Futibatinib, by Cysteinomix Drug Discovery Approach
Time: 3:00 pm
day: Conference Day Two
Details:
- What is the optimal profile of a covalent drug targeting FGFRs, considering target engagement, PKPD, safety and tolerability?
- How to design covalent binding drugs to capture Cys on highly flexible loop structures
- What is the desirable platform to continuously deliver covalent binding drug candidates into clinical space?
